{Reference Type}: Journal Article
{Title}: Cancer history: A predictor of IPMN subtype and dysplastic status?
{Author}: Carr RA;Kiel BA;Roch AM;Ceppa EP;House MG;Zyromski NJ;Nakeeb A;Schmidt CM;
{Journal}: Am J Surg
{Volume}: 215
{Issue}: 3
{Year}: Mar 2018
{Factor}: 3.125
{DOI}: 10.1016/j.amjsurg.2017.11.014
{Abstract}: <B>BACKGROUND: </B>The aim of this study was to determine the association of PMH and FH of pancreatic (PDAC) and non-pancreatic cancers with IPMN malignant risk.<BR><B>METHODS: </B>A retrospective review of a prospective database of IPMN patients undergoing resection was performed to assess FH and PMH.<BR><B>RESULTS: </B>FH of PDAC was present in 13% of 362 included patients. Of these, 8% had at least one first degree relative (FDR) with PDAC. The rate of PDAC positive FH in non-invasive versus invasive IPMN patients was 14% and 8%, respectively (p = 0.3). In main duct IPMN patients, FH (44%) and PMH of non-pancreatic cancer (16%) was higher than that seen in branch duct IPMN (FH 29%; PMH 6%; p = 0.004 and 0.008).<BR><B>CONCLUSIONS: </B>FH of PDAC is not associated with IPMN malignant progression. FH and PMH of non-pancreatic cancer is associated with main duct IPMN, the subtype with the highest rate of invasive transformation.